Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway

Figure 4

TGF-β1 blocker treatment attenuates expression and function of profibrotic markers in IL-19-stimulated lung fibroblasts. (a) The bioinformatics KEGG functional enrichment analysis of IL-19 in IPF patients and BLM-induced pulmonary fibrosis mouse lung tissues. (b) the western blots were used to analysis the expression of TGF-β1, Smad2/3, p-Smad3, Col-1, and α-SMA in lung fibroblasts treated with increased IL-19 concentration of 0, 10, 100, and 200 ng/ml, and (d) relative protein levels were quantified. Data were compared with NC group. (c) IL-19-stimulated lung fibroblasts treated with LY2109761 at concentration of 0.5–10 μM for 72 h, and (e) relative protein levels were quantified. Data were compared with IL-19 group. (f) Lung fibroblasts were treated with IL-19 (100 ng/ml) or or IL-19 , cell appreciate rates were assessed by CCK-8 assay at 0 h, 24 h, 48 h, and 72 h, and (g) 72 h cell appreciate rates were analyzed. (h) Cell invasions were analyzed by transwell assay and (i) numbers of migrated cells were quantified. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)